|Mr. Christopher Simon||Chief Exec. Officer, Pres and Director||1.51M||N/A||53|
|Mr. William P. Burke||Chief Financial Officer and Exec. VP||1.03M||N/A||N/A|
|Mr. Neil Ryding||Exec. VP of Global Operations||944.56k||N/A||56|
|Mr. Dan Goldstein||Principal Accounting Officer, VP and Corp. Controller||N/A||N/A||40|
|Mr. Gerard J. Gould||VP of Investor Relations||N/A||N/A||63|
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer system, a blood diagnostic instrument that measure a patients hemostasis or the ability to form and maintain blood clots; Cell Saver system, a surgical blood salvage system for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it offers SafeTrace Tx, a software solution that manages blood product inventory and transfusion, as well as performs patient cross-matching; and BloodTrack suite of solutions for managing, tracking, and controlling blood products from the hospital blood center through to transfusion to the patient. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Haemonetics Corporation’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 7; Compensation: 2.